Biktarvy® (BIC/FTC/TAF)
Treatment Emergent RAMs
Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.
Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.
Biktarvy® (BIC/FTC/TAF)
Treatment-Emergent RAMs
Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.
The full indication, important safety information, and boxed warnings are available at:
www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.
Summary
Gilead Phase 3 Clinical Trial Data on BIC/FTC/TAF Use and Treatment-Emergent RAMs
No treatment-emergent RAMs were detected in >3000 PWH who received BIC/FTC/TAF in Gilead-sponsored phase 3 clinical trials.1-10
Real-World Data on BIC/FTC/TAF Use and Treatment-Emergent RAMs
In a retrospective study that used data from the HealthVerity database to assess the incidence of treatment-emergent RAMs among PWH who received oral ARV treatment, including BIC/FTC/TAF (n=108,721), from 2018 to 2024, the incidence of RAMs was 280/108,721 with BIC/FTC/TAF. Overall adherence was high in 68% of patients who received BIC/FTC/TAF; among patients who developed RAMs, adherence in the 90 days prior to RAM outcome was high in 15% of patients, mixed in 8%, and low in 77%.11
In a retrospective study that used data from a national French database of genotypic resistance assays to assess treatment-emergent resistance in PWH, including those who received BIC/FTC/TAF (N=3383), 3% of participants (6/203) who received BIC/FTC/TAF and had confirmed VF developed treatment-emergent RAMs (M184V, n=4; dual INSTI and M184V, n=2).12
In BICSTaR, an ongoing, multicountry, prospective, observational cohort study in PWH that is evaluating the effectiveness and safety of BIC/FTC/TAF in clinical practice, no treatment‑emergent RAMs to the components of BIC/FTC/TAF were detected at 24 months (ARV-naive, n=483; TE, n=1591), 36 months (ARV-naive, n=67; TE, n=382), 4 years (ARV-naive, n=125; TE, n=675), or 5 years (ARV-naive, n=132; TE, n=691).13-16
Gilead Phase 3 Clinical Trial Data on BIC/FTC/TAF Use and Treatment‑Emergent RAMs
No treatment-emergent RAMs were detected in >3000 PWH treated with BIC/FTC/TAF in Gilead-sponsored phase 3 clinical trials (Table 1).1-10,17
Table 1. Treatment-Emergent RAMs in BIC/FTC/TAF Phase 3 Clinical Trials (BIC/FTC/TAF-Treated Participants)1-10,17
Trial | Population | Na | Drugs With Excluded Resistanceb | Treatment- Emergent RAMsc |
GS-US-380-14891 | ARV-naive adults | 314/254 | FTC, TFV, ABC, and 3TC18 | No |
GS-US-380-14901 | ARV-naive adults | 320/265 | FTC and TFV19 | No |
GS-US-380-18782 | VS adults | 290/244 | FTC, TFV, ABC, and 3TC | No |
GS-US-380-18443 | VS adults | 284/265 | FTC, TFV, DTG, ABC, and 3TC20 | No |
GS-US-380-40304 | VS adults | 284 | INSTI | No |
GS-US-380-19615 | VS adult women | 234/228 | FTC, TFV, ATV, and EVG21 | No |
BRAAVE 20206 | VS adults self‑identifying as Black or African American | 330/163 | INSTI and specific NRTI RAMs (ie, K65R/E/N, T69 insertions, ≥3 TAMs) | No |
VS adolescents and children | 122 | FTC, TFV, and INSTI22 | No | |
GS-US-380-44499 | VS adults ≥65 years of age | 86 | FTC, TFV, and BIC22 | No |
ALLIANCE GS-US-380-445810 | ARV-naive adults with HIV and HBV | 119/89 | FTC and TFV17 | No |
Abbreviations: 3TC=lamivudine; ABC=abacavir; ATV=atazanavir; DTG=dolutegravir; EVG=elvitegravir; TAM=thymidine analog mutation; TFV=tenofovir; VS=virologically suppressed.
aTotal number of participants includes those randomly assigned to receive BIC/FTC/TAF at baseline/those who later switched to BIC/FTC/TAF if the study included an extension phase.
bThe trial excluded participants with resistance to the drugs listed.
cResistance testing performed for participants with confirmed viremia with second HIV-1 RNA ≥200 c/mL or ≥200 c/mL at last visit, with no resuppression of HIV-1 RNA to <50 c/mL while on study drug.
Real-World Data on BIC/FTC/TAF Use and Treatment‑Emergent RAMs
Retrospective Study of RAMs With BIC/FTC/TAF11
A retrospective study using data from the HealthVerity database assessed the incidence of treatment-emergent RAMs in adult PWH on oral ARV treatment, including BIC/FTC/TAF (n=108,721), from 2018 to 2024. Outcomes included newly detected RAMs after ≥90 days on one of the index regimens, mutations associated with resistance to ≥1 component of the regimen, associated viremia (HIV-1 RNA ≥200 c/mL), and adherence during the 90 days leading up to RAM detection, as assessed by PDC.
The unweighted incidence of RAMs with BIC/FTC/TAF was 280/108,721. Among all patients who received BIC/FTC/TAF, 68% had high adherence (PDC, 85–100%), 15% had mixed adherence (PDC, 65–84%), and 17% had low adherence (PDC, <65%). Among patients who received BIC/FTC/TAF and developed RAMs, adherence in the 90 days prior to RAM outcome was high in 15% of patients, mixed in 8%, and low in 77%.
French National Database Study12
A multicenter, retrospective, observational study used data from a French national database of genotypic resistance assays to assess treatment‑emergent resistance in PWH, including those who received BIC/FTC/TAF (N=3383). Included were adults with a history of ≥1 ARV regimen with genotypic resistance assay results from either the first-line ARV regimen or the last confirmed VF (two consecutive HIV-1 viral loads >50 c/mL) between January 2022 and December 2024. The primary outcome was the proportion of treatment‑emergent RAMs in patients with confirmed VF, and secondary outcomes included treatment-emergent INSTI RAMs and NRTI RAMs in patients who received BIC/FTC/TAF.
Over 3 years of follow-up, the incidence of confirmed VF with BIC/FTC/TAF was 6% (203/3383); of those patients, treatment-emergent RAMs were detected in 3% (6/203). Of the 6 patients with treatment-emergent RAMs, 4 patients (67%) had the NRTI RAM M184V alone, and 2 (33%) had dual INSTI (E138K or N155H) and M184V RAMs.
BICSTaR Study
BICSTaR is a Gilead-sponsored, ongoing, multicountry, prospective, observational cohort study in PWH that is evaluating the effectiveness, safety, and tolerability of BIC/FTC/TAF in clinical practice. ARV-naive (n=483) and TE (n=1591) PWH were evaluated in a 24-month pooled analysis of data from clinical sites in Europe, Canada, Israel, Asia, and Japan (June 27, 2018–December 20, 2023). Pooled analyses of data collected through 36 months (data cutoff, August 12, 2022; ARV-naive, n=67; TE, n=382), 4 years (data cutoff, September 1, 2023; ARV-naive, n=125; TE, n=675), and 5 years (data cutoff, June 24, 2024; ARV-naive, n=132; TE, n=691) from clinical sites in Germany, France, and Canada were also conducted. No treatment‑emergent RAMs to the components of BIC/FTC/TAF were detected at 24 months, 36 months, 4 years, or 5 years.13-16
References
Abbreviations
Page 1 of 6
ARV=antiretroviral
BIC=bictegravir
BICSTaR=BIC Single Tablet Regimen
c/mL=copies/mL
FTC=emtricitabine
INSTI=integrase strand transfer inhibitor
MTR=multitablet regimen
NRTI=nucleos(t)ide reverse transcriptase inhibitor
PDC=percentage of days covered
PWH=people with HIV-1
RAM=resistance-associated mutation
TAF=tenofovir alafenamide
TE=treatment experienced
VF=virologic failure
Product Label
For the full indication, important safety information, and boxed warning(s), please refer to the Biktarvy US Prescribing Information available at:
www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.
Follow-Up
For any additional questions, please contact Gilead Medical Information at:
☎1‐866‐MEDI‐GSI (1‐866‐633‐4474) or www.askgileadmedical.com
Adverse Event Reporting
Please report all adverse events to:
Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
https://www.gilead.com/utility/contact/report-an-adverse-event
FDA MedWatch Program by ☎ 1-800-FDA-1088 or MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or www.accessdata.fda.gov/scripts/medwatch
Data Privacy
The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.
It may be necessary for us to share your information with Gilead’s affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.
BIKTARVY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
© 2026 Gilead Sciences, Inc.
Page 1 of 6